Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells

Mutations in EGFR correlate with impaired response to immune checkpoint inhibitors and the development of novel immunotherapeutic approaches for EGFR mutant NSCLC is of particular interest. Immunization against epidermal growth factor (EGF) has shown efficacy in a phase III trial including unselecte...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2018-09, Vol.13 (9), p.1324-1337
Hauptverfasser:	Codony-Servat, Jordi, García-Roman, Silvia, Molina-Vila, Miguel Ángel, Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Viteri, Santiago, Cardona, Andrés F, D’Hondt, Erik, Karachaliou, Niki, Rosell, Rafael
Format:	Artikel
Sprache:	eng
Schlagworte:	antibody EGF NSCLC resistance tyrosine kinase inhibitors vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!